Logo image of STXS

STEREOTAXIS INC (STXS) Stock Fundamental Analysis

NYSEARCA:STXS - NYSE Arca - US85916J4094 - Common Stock - Currency: USD

2.2  +0.04 (+1.85%)

After market: 2.2 0 (0%)

Fundamental Rating

2

STXS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. STXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. STXS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year STXS has reported negative net income.
STXS had a negative operating cash flow in the past year.
In the past 5 years STXS always reported negative net income.
In the past 5 years STXS always reported negative operating cash flow.
STXS Yearly Net Income VS EBIT VS OCF VS FCFSTXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -58.31%, STXS is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
STXS's Return On Equity of -325.98% is on the low side compared to the rest of the industry. STXS is outperformed by 81.82% of its industry peers.
Industry RankSector Rank
ROA -58.31%
ROE -325.98%
ROIC N/A
ROA(3y)-47.89%
ROA(5y)-35.58%
ROE(3y)-127.97%
ROE(5y)-86.89%
ROIC(3y)N/A
ROIC(5y)N/A
STXS Yearly ROA, ROE, ROICSTXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

STXS has a Gross Margin (53.41%) which is comparable to the rest of the industry.
STXS's Gross Margin has declined in the last couple of years.
STXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.5%
GM growth 5Y-7.2%
STXS Yearly Profit, Operating, Gross MarginsSTXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

STXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STXS has been increased compared to 1 year ago.
The number of shares outstanding for STXS has been increased compared to 5 years ago.
There is no outstanding debt for STXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STXS Yearly Shares OutstandingSTXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
STXS Yearly Total Debt VS Total AssetsSTXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -15.59, we must say that STXS is in the distress zone and has some risk of bankruptcy.
STXS has a Altman-Z score of -15.59. This is amonst the worse of the industry: STXS underperforms 88.24% of its industry peers.
STXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.59
ROIC/WACCN/A
WACC8.99%
STXS Yearly LT Debt VS Equity VS FCFSTXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.07 indicates that STXS should not have too much problems paying its short term obligations.
STXS's Current ratio of 1.07 is on the low side compared to the rest of the industry. STXS is outperformed by 88.24% of its industry peers.
STXS has a Quick Ratio of 1.07. This is a bad value and indicates that STXS is not financially healthy enough and could expect problems in meeting its short term obligations.
STXS has a Quick ratio of 0.66. This is amonst the worse of the industry: STXS underperforms 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.66
STXS Yearly Current Assets VS Current LiabilitesSTXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

STXS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.81%.
Looking at the last year, STXS shows a small growth in Revenue. The Revenue has grown by 1.49% in the last year.
The Revenue has been decreasing by -1.41% on average over the past years.
EPS 1Y (TTM)-14.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)1.49%
Revenue growth 3Y-8.4%
Revenue growth 5Y-1.41%
Sales Q2Q%8.6%

3.2 Future

The Earnings Per Share is expected to grow by 24.55% on average over the next years. This is a very strong growth
STXS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.18% yearly.
EPS Next Y8.2%
EPS Next 2Y25.5%
EPS Next 3Y24.55%
EPS Next 5YN/A
Revenue Next Year22.04%
Revenue Next 2Y39.98%
Revenue Next 3Y40.18%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
STXS Yearly Revenue VS EstimatesSTXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
STXS Yearly EPS VS EstimatesSTXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STXS. In the last year negative earnings were reported.
Also next year STXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STXS Price Earnings VS Forward Price EarningsSTXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STXS Per share dataSTXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as STXS's earnings are expected to grow with 24.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.5%
EPS Next 3Y24.55%

More info and screens

0

5. Dividend

5.1 Amount

STXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STEREOTAXIS INC

NYSEARCA:STXS (7/3/2025, 8:11:12 PM)

After market: 2.2 0 (0%)

2.2

+0.04 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners47.52%
Inst Owner Change-2.55%
Ins Owners20.37%
Ins Owner Change7.62%
Market Cap189.20M
Analysts82
Price Target4.59 (108.64%)
Short Float %6.26%
Short Ratio14.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.2%
Min EPS beat(2)-35.75%
Max EPS beat(2)5.34%
EPS beat(4)1
Avg EPS beat(4)-27.63%
Min EPS beat(4)-49.39%
Max EPS beat(4)5.34%
EPS beat(8)3
Avg EPS beat(8)-14.71%
EPS beat(12)4
Avg EPS beat(12)-12.81%
EPS beat(16)6
Avg EPS beat(16)-16.07%
Revenue beat(2)1
Avg Revenue beat(2)1.64%
Min Revenue beat(2)-3.27%
Max Revenue beat(2)6.54%
Revenue beat(4)2
Avg Revenue beat(4)2.18%
Min Revenue beat(4)-21.54%
Max Revenue beat(4)26.98%
Revenue beat(8)3
Avg Revenue beat(8)-3.64%
Revenue beat(12)3
Avg Revenue beat(12)-5.94%
Revenue beat(16)6
Avg Revenue beat(16)-3.47%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-42.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.88
P/FCF N/A
P/OCF N/A
P/B 23.14
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.32
BVpS0.1
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.31%
ROE -325.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.41%
FCFM N/A
ROA(3y)-47.89%
ROA(5y)-35.58%
ROE(3y)-127.97%
ROE(5y)-86.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.5%
GM growth 5Y-7.2%
F-Score2
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.84%
Cap/Sales 0.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 0.66
Altman-Z -15.59
F-Score2
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)206.17%
Cap/Depr(5y)389.02%
Cap/Sales(3y)3.32%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y8.2%
EPS Next 2Y25.5%
EPS Next 3Y24.55%
EPS Next 5YN/A
Revenue 1Y (TTM)1.49%
Revenue growth 3Y-8.4%
Revenue growth 5Y-1.41%
Sales Q2Q%8.6%
Revenue Next Year22.04%
Revenue Next 2Y39.98%
Revenue Next 3Y40.18%
Revenue Next 5YN/A
EBIT growth 1Y-23.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.18%
OCF growth 3YN/A
OCF growth 5YN/A